Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience

Full text
Author(s):
Maesta, Izildinha [1, 2, 3] ; Nitecki, Roni [4] ; Horowitz, Neil S. [5, 6, 7, 8] ; Goldstein, Donald P. [5, 6, 7, 8] ; Segalla Moreira, Marjory de Freitas [1, 2, 3] ; Elias, Kevin M. [5, 6, 7, 8] ; Berkowitz, Ross S. [5, 6, 7, 8]
Total Authors: 7
Affiliation:
[1] Sao Paulo State Univ, UNESP, Botucatu Med Sch, Dept Gynecol & Obstet, Botucatu, SP - Brazil
[2] Sao Paulo State Univ, UNESP, Botucatu Med Sch, Trophoblast Dis Ctr, Botucatu, SP - Brazil
[3] Sao Paulo State Univ, UNESP, Botucatu Med Sch, Postgrad Program Gynecol Obstet & Mastol, Botucatu, SP - Brazil
[4] Brigham & Womens Hosp, Dept Obstet & Gynecol, 75 Francis St, Boston, MA 02115 - USA
[5] Harvard Med Sch, Boston, MA - USA
[6] Brigham & Womens Hosp, Dept Obstet & Gynecol, Div Gynecol Oncol, 75 Francis St, Boston, MA 02115 - USA
[7] New England Trophoblast Dis Ctr, Donald P Goldstein MD Tumor Registry, Boston, MA - USA
[8] Harvard Canc Ctr, Dana Farber Canc Inst, Boston, MA - USA
Total Affiliations: 8
Document type: Journal article
Source: GYNECOLOGIC ONCOLOGY; v. 148, n. 1, p. 161-167, JAN 2018.
Web of Science Citations: 8
Abstract

Objectives. To assess the outcomes and toxicity of first-line methotrexate (MTX) chemotherapy in low-risk postmolar gestational trophoblastic neoplasia (GTN) patients receiving 8-day methotrexate or one-day methotrexate infusion regimens. Methods. This retrospective cohort study was conducted at the New England Trophoblastic Disease Center (NETDC), between 1974 and 2014, and included 325 patients with FIGO-defined low-risk postmolar GTN receiving first-line 8-day MTX/folinic acid (FA) or one-day MTX infusion and FA. Demographics, disease presentation, initial treatment plan, treatment outcome, and treatment-related adverse events were assessed. Results. Sustained remission (84% vs 62%, p < 0.001) and need to switch to second-line therapy due to treatment-related adverse events (53% vs 0%, p = 0.001) were higher for 8-day MTX/FA compared to one-day MIX infusion. MTX resistance, however, was more frequent with one-day MTX (34.5%) than with 8-day MTX/ FA (7.3%, p < 0.001). Relapse rates were similar with both regimens (3.0%). Compared to one-day MTX infusion, 8-day MTX/FA was associated with significantly higher gastrointestinal disorders (48% vs 24%), abnormal laboratory findings (48% vs 28%), eye disorders (37% vs 19%) and general disorders (22% vs 5%) (p < 0.001). Only infection frequency did not differ between 8-day MTX/FA and one-day MTX infusion (20% vs 12%, p = 0.083). Conclusions. This is one of the largest studies to comprehensively catalogue toxicities associated with 8-day MTX/FA and one-day MTX infusion. Although treatment-related adverse events were more frequent with 8 day MTX/FA, these were all self-limited and resolved with no long-term sequelae. Given this and its higher effectiveness, 8-day MTX/FA remains the treatment of choice at NETDC for patients with low-risk postmolar GTN. (C) 2017 Published by Elsevier Inc. (AU)

FAPESP's process: 15/12530-0 - Efficacy and toxicity of two different schedules of methotrexate/folinic acid therapy in patients with low-risk postmolar gestational trophoblastic neoplasia
Grantee:Izildinha Maestá
Support Opportunities: Scholarships abroad - Research